Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials
Abstract A joint modeling framework was developed using data from 75 patients of early amcenestrant phase I-II AMEERA‐1‐2 dose escalation and expansion cohorts. A semi‐mechanistic tumor growth inhibition (TGI) model was developed. It accounts for the dynamics of sensitive and resistant tumor cells,...
Saved in:
Main Authors: | Marc Cerou (Author), Hoai‐Thu Thai (Author), Laure Deyme (Author), Sophie Fliscounakis‐Huynh (Author), Emmanuelle Comets (Author), Patrick Cohen (Author), Sylvaine Cartot‐Cotton (Author), Christine Veyrat‐Follet (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients
by: Hoai‐Thu Thai, et al.
Published: (2023) -
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
by: Kimiko Koiwai, et al.
Published: (2021) -
Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma
by: Fatiha Rachedi, et al.
Published: (2022) -
Mechanistic models for hematological toxicities: Small is beautiful
by: Laure Deyme, et al.
Published: (2021) -
Advanced Cervical Cancer: Leveraging the Historical Threshold of Overall Survival
by: Eduardo Paulino, et al.
Published: (2021)